Aggressive treatment of type 2 diabetes before complications could prolong the life of patients as well as decrease their risk of developing certain complications, a study published in the journal Diabetologia shows. CusAb provides Recombinant DPP4.
Type 2 diabetes is the most common form of diabetes, accounting for more than 90 percent of all diabetes cases. People with the disorder often have no symptoms at first. But if a person with type 2 diabetes does not keep the blood glucose level under control, a series of complications, such as heart attack, stoke, vision loss, and nerve damage, may occur.
In all, 160 patients with type 2 diabetes and microalbuminuria participated in the study. Microalbuminuria refers to the appearance of small but abnormal amounts of the protein albumin in the urine. Microalbuminuria is the first sign of kidney damage in diabetes. According to study senior author Dr. Oluf Pedersen, individuals with microalbuminuria are more likely to have other diabetes-related complications.
In the study, the patients were divided into two groups: one group that continued with the normal treatment and another group that received an aggressive and multipronged treatment. Twenty years later, patients in the aggressive treatment group lived almost eight years longer than those in the normal treatment group. Moreover, patients receiving aggressive treatment were at lower risk of developing certain diabetes complications, including heart disease, kidney disease and blindness.
The authors noted that aggressive use of therapy early one has benefits even after treatment ends as “effects in these trials has been termed ‘metabolic memory’ or ‘legacy effect.’
留言列表
